San Francisco, 14 May 2024: The Report Hereditary Testing Market Size, Share & Trends Analysis Report By Disease Type (Hereditary Cancer Testing, Hereditary Non-cancer Testing), By Technology (Cytogenetic, Biochemical, Molecular Testing), By Region, And Segment Forecasts, 2023 - 2030

The global hereditary testing market size is expected to reach USD 12.73 billion by 2030, registering a CAGR of 8.4% over the forecast period, according to a new report by Grand View Research, Inc. Key factors driving the market are the declining cost of sequencing and the availability of genetic tests at a lower price. Furthermore, the availability of niche and fragmented point solutions across the genomics value chain, namely sequencing, analytics, interpretation, aggregation, and marketplace, is anticipated to propel the market growth over the forecast period.

The advent of direct-to-consumer genetics is anticipated to play a major role in the genetic testing market by enabling individuals to carry out self-testing. This expands the role of genetic counselors, which further aids in understanding the importance of genetic tests and helps in the selection of appropriate tests. A growing number of registered genetic counselors is anticipated to boost the adoption of hereditary genetic tests in the coming years.

Another important market trend is the growing field of reproductive genetic health. For instance, Natera has seen a consistent increase in test numbers in hereditary illnesses genetic analysis for women's health. This indicates a rise in public acceptance of hereditary testing, which is fueling the market expansion. A rise in the trade of newborn screening equipment has corresponded with a rise in the trade of DNA experiment equipment. Progressing the sharpness of newborn screening all over the world is also assisting in earnings increase. A multigene board trial was formed for introducing genetic melanoma into the clinical application, which has been prompted by changes in genetic experimentation standards. The growing generative hereditary health scope is one of the most important key factors driving the market.

The COVID-19 pandemic had a detrimental impact on the market. For example, after the World Health Organization declared COVID-19 a pandemic, governments all around the world used lockdowns to compel social distancing as a prophylactic measure. In every industry, this resulted in upheaval, constraints, challenges, and adjustments. Similarly, the outbreak has a negative impact on the inherited genetic analysis sector.

Technology developers are introducing advanced products to enhance the efficiency of genetic tests by diagnostic companies. For example, in December 2020, the QuantiFERON SARS-CoV-2 RUO solution was introduced by QIAGEN, a business that provides technologies and products for pre-analytical samples and related molecular test solutions. The solution detects immune system T-cell responses to the infection that causes COVID-19. The solution would give precise information on illness development and immunity levels.

Request sample report of Hereditary Testing Market@ https://www.grandviewresearch.com/industry-analysis/hereditary-testing-market/request/rs1

The expanding reproductive genetic health space is one of the key market drivers. Key players such as Natera have reported a continuous increase in test volumes in women’s health genetic testing for inherited conditions. This reflects the growing acceptance of hereditary tests among the population, thereby accelerating revenue growth. COVID-19 had a detrimental impact on the market. For example, after the World Health Organization declared COVID-19 a pandemic, governments all around the world used lockdowns to compel social separation as a prophylactic measure. In every industry, this resulted in upheaval, constraints, challenges, and adjustments.

Hereditary Testing Market Report Highlights

• The hereditary cancer testing disease type segment dominated the market with a revenue share of over 80.0% in 2022 and is expected to expand at a significant CAGR over the forecast period. A substantial number of CLIA-certified laboratories perform tests to determine whether an individual carries an inherited mutated gene that can cause cancer
• The breast cancer testing segment dominated the hereditary cancer testing market in 2021 owing to its high penetration and increased inheritability. Most of the cases of cervical cancer are non-hereditary, resulting in the lowest revenue share of this segment
• In the hereditary non-cancer testing disease type segment, the cardiac diseases segment is driven by the emergence of high-throughput sequencing, which has resulted in the commercial availability of a significant number of sequencing assays for cardiomyopathies
• The Non-invasive Prenatal Testing (NIPT) and cancer screening tests segment and the newborn genetic screening segment continue to witness lucrative growth due to the increased adoption across the globe
• Moreover, the newborn screening program has been made mandatory in several regions and countries, resulting in the growth of newborn genetic screening in the hereditary non-cancer testing disease type segment
• Europe accounted for the largest revenue share of over 34.8% in 2022 owing to the assisted reproductive technology space, coupled with the high penetration of newborn genetic screening
• Key companies are engaged in securing regulatory approval in emerging countries to expand their business footprint. A substantial number of diagnostic companies have collaborated with technology developers to obtain technology licenses and deliver high-value services to their customers

Similarly, the outbreak negatively impacted the inherited genetic analysis sector. This is due to the incapacity of genetic counselors to see clients in person, the failure of doctors to provide guidance, and the laboratory's inability to do the tests. Furthermore, because regulatory bodies such as the Centers for Medicaid Services (CMS) did not recognize genetic counselors as healthcare practitioners, they were prohibited from working during government shutdowns. Clinics also limited face-to-face diagnostic tests to help prevent the disease from spreading. Nonetheless, genetic testing behemoths such as GeneDx provided clinician-ordered genetic screening as a service. Clinics and healthcare practitioners as well as people used telemedicine to provide genetic counseling.

Furthermore, a consistent rise in demand for newborn screening has led to an increase in sales of DNA testing kits. Increasing penetration of newborn screening across the globe is further aiding in revenue growth. Reforms in genetic testing guidelines have led to the inclusion of multigene panel testing for hereditary cancer into clinical practice. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast, ovarian, and colorectal cancers offer information on some of the cancer risk factors and management.

The need for genetic testing has increased, resulting in an increase in DNA screening kit purchases. The Virginia Department of General Services Division of Integrated Laboratory Facilities, for example, screened 7,867 newborns for over 31 genetic and metabolic illnesses in November 2023. Increased adoption of newborn screening throughout the world is also contributing to market expansion. The application of multigene panel screening in clinics for hereditary disorders has increased, which is due to the changes in the genetic testing procedures. Moreover, favorable initiatives undertaken by government bodies are further expected to drive the market growth. For instance, in March 2023 , the Ministry of Health, Welfare and Sport of Netherlands announced that the NIPT tests accessible to all pregnant women in the country starting from April 1st, 2023.This proactive measure is expected to significantly contribute to the expansion of the market.

Hereditary Testing Market Report Scope

The National Comprehensive Cancer Network offers information on numerous cancer risk factors as well as treatment guidelines for single and multiple genetic panels. Gradual improvements in distribution strategy are expected to benefit the inherited genetic testing business. By improving distribution services and expanding technical efficiency, technological providers are helping to expand the market. To make bioinformatics technologies available to other universities, companies are using a cloud-based distribution model. Around 14 licensees began actively marketing Non-invasive Prenatal Testing devices utilizing constellation software. Although these hereditary tests have significant advantages over conventional tests, several industry experts cited the cost and security concerns faced by consumers pertaining to the test. Moreover, the lack of effective regulation of the tests is another key area that demands focused efforts. Despite these challenges, the genetic testing market is constantly expanding owing to the advantages of these innovative tests along with improved healthcare outcomes.

List of Key Players in the Hereditary Testing Market

• Myriad Genetics, Inc.
• Invitae Corporation
• Illumina, Inc.
• Natera, Inc.
• Laboratory Corporation of America Holdings
• F. Hoffmann-La Roche Ltd.
• Quest Diagnostics Incorporated
• COOPERSURGICAL, INC.
• Agilent Technologies, Inc.